Infliximab in treatment of PVR
Reviewed by Kurt Spiteri Cornish

In this phase 2 randomly controlled trial, 66 patients with primary rhegmatogenous retinal detachment and grade C proliferative vitreoretinopathy (PVR) were randomised in a 1:1 ratio to undergo pars plana vitrectomy (PPV) and silicone oil (SO) injection with or without intravitreal injection of 1m/0.05mL of infliximab in the air-filled globe before SO injection at PPV conclusion. Primary outcome was anatomic success, i.e. complete retinal reattachment without tamponade at six months after SO removal. Sixty eyes were included in the study analysis. Baseline characteristics were comparable between the groups, as were the surgical details including presence of partial or complete posterior vitreous detachment, iatrogenic breaks, membrane peeling and retinectomy rates. The final anatomic success rate was similar between both groups. The final best corrected visual acuity was better in the infliximab group (logMAR 0.96) than the other group (1.14; p=0.044). The authors state that this modest visual benefit needs to be investigated further with future studies. It may reflect the decrease in inflammatory damage to the photoreceptors. Final central macular thickness, postoperative multifocal electroretinogram and optical coherence tomography measurements were similar between the groups.

Intravitreal infliximab for the treatment of proliferative vitreoretinopathy (fixer): a randomized controlled phase II trial.
Younes AM, Hamza HS, Omar HA, et al.
OPHTHALMOLOGY RETINA
2024;8(11):1044–51.